Hybrid Stage 3 Fontan Procedure

Charting New Horizons in Congenital Heart Care: IJN's Breakthrough for Fontan Patients. Delve into the realm of Fontan procedure as we unveil a pioneering solution. From addressing the uncommon condition affecting 5-10% to introducing the AFR device, witness how IJN's innovative approach aims to transform the lives of young patients facing complications. Explore the purpose of the Fontan procedure, the unique challenges, and the groundbreaking solution that may redefine the future of congenital

As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD). The findings, published last week in Science Translational Medicine, reveal insights into how the disease develops and potential therapeutic targets for future treat